Lyell strong ronde-cel responses in pivotal 3L+ LBCL PiNACLE trial with favorable safety
Lyell Immunopharma reports strong ronde-cel responses in pivotal 3L+ LBCL PiNACLE trial with favorable safety ahead of ASH 2026
- Updated pivotal 3L+ LBCL PiNACLE cohort data show 91% overall response rate and 77% complete response rate.
- In the 2L LBCL cohort, ronde-cel achieved 95% overall response rate and 76% complete response rate.
- Safety profile in both 3L+ and 2L PiNACLE cohorts reported as favorable in the updated ronde-cel data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.